Literature DB >> 2158470

[Rectal micropolyps after total colectomy in familial polyposis. Efficacy of sulindac].

J Charneau1, N D'Aubigny, P Burtin, B Person, J Boyer.   

Abstract

The aim of this study was to assess the effectiveness of sulindac therapy for eradication of micropolyps in 8 patients with familial polyposis coli. All patients had undergone colectomy and ileoproctostomy 4.5 years (range 3 months-20 years) before and had tubulous adenomas micropolyps in the rectum. Initial sulindac therapy 200 mg or 300 mg daily was started in all patients and was continued in 7 patients. In these 7 patients macroscopic and microscopic eradication of micropolyps was obtained within 3.4 months (1-8). After discontinuation of sulindac therapy, recurrence of micropolyps occurred in 4 patients within 3 to 4 months. Three patients had no recurrence with a follow-up of 1 to 19 months. A new eradication of micropolyps was obtained in these 4 patients with a second sulindac cure within 3 to 6 months. These observations confirm the effectiveness of sulindac therapy for eradication of tubulous adenomas micropolyps in familial polyposis, but after discontinuation of therapy, recurrence is frequent. Continuous or intermittent therapy might reduce recurrence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158470

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  4 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Discouraging colonic polyps.

Authors:  C B Williams
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 3.  Sulindac and polyp regression.

Authors:  F M Giardiello
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

4.  The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration.

Authors:  G Winde; H G Gumbinger; H Osswald; F Kemper; H Bünte
Journal:  Int J Colorectal Dis       Date:  1993-03       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.